TME Pharma N.V. (EPA:ALTME)

Market Cap	7.96M -9.1%
Revenue (ttm)	n/a
Net Income	-3.29M
EPS	-0.03
Shares Out	94.09M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	86,725
Open	0.0851
Previous Close	0.0869
Day's Range	0.0802 - 0.0866
52-Week Range	0.0490 - 0.1480
Beta	0.64
Analysts	n/a
Price Target	n/a
Earnings Date	May 7, 2026

About TME Pharma

TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. The company’s Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, and glioblastoma. It also developing NOX-E36, which has completed Phase 1/2a clinical trial for the treatme...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1997
• Employees: 12
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALTME